Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/69346
Title: FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies
Author: Martínez-Aranda, Antonio
Hernández, Vanessa
Guney, Emre
Muixí, Laia
Foj, Ruben
Baixeras, Núria
Cuadras, Daniel
Moreno, Víctor
Urruticoechea, Ander
Gil, Miguel
Oliva, Baldo
Moreno, Ferran
González-Suarez, Eva
Vidal, Noemí
Andreu, Xavier
Seguí, Miquel A.
Ballester, Rosa
Castella, Eva
Sierra, Àngels
Keywords: Marcadors bioquímics
Càncer de mama
Melanoma
Metàstasi
Biochemical markers
Breast cancer
Melanoma
Metastasis
Issue Date: 19-Oct-2015
Publisher: Impact Journals
Abstract: Brain metastasis is a devastating problem in patients with breast, lung and melanoma tumors. GRP94 and FN14 are predictive biomarkers over-expressed in primary breast carcinomas that metastasized in brain. To further validate these brain metastasis biomarkers, we performed a multicenter study including 318 patients with breast carcinomas. Among these patients, there were 138 patients with metastasis, of whom 84 had brain metastasis. The likelihood of developing brain metastasis increased by 5.24-fold (95%CI 2.83-9.71) and 2.55- (95%CI 1.52-4.3) in the presence of FN14 and GRP94, respectively. Moreover, FN14 was more sensitive than ErbB2 (38.27 vs. 24.68) with similar specificity (89.43 vs. 89.55) to predict brain metastasis and had identical prognostic value than triple negative patients (p < 0.0001). Furthermore, we used GRP94 and FN14 pathways and GUILD, a network-based disease-gene prioritization program, to pinpoint the genes likely to be therapeutic targets, which resulted in FN14 as the main modulator and thalidomide as the best scored drug. The treatment of mice with brain metastasis improves survival decreasing reactive astrocytes and angiogenesis, and down-regulate FN14 and its ligand TWEAK. In conclusion our results indicate that FN14 and GRP94 are prediction/prognosis markers which open up new possibilities for preventing/treating brain metastasis.
It is part of: Oncotarget, 2015, vol. 6, núm. 42, p. 44255-44273
Related resource: http://dx.doi.org/10.18632/oncotarget.5471
URI: http://hdl.handle.net/2445/69346
ISSN: 1949-2553
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
FN14 and GRP94 expression are prognostic predictive biomarkers_Oncotarget_2015.pdf6.66 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons